StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.40+0.40 (+2.22%)

Close on Nov 18, 2026Market cap $2.94BP/E –Yield –

Denali Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Denali Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$437.46M. For fiscal 2025 it was -$422.10M. The highest annual figure on record is $413.06M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$422.10M–
FY2024Dec 31, 2024-$363.61M–
FY2023Dec 31, 2023-$370.93M–
FY2022Dec 31, 2022-$262.55M–
FY2021Dec 31, 2021-$219.89M-153.2%
FY2020Dec 31, 2020$413.06M–
FY2019Dec 31, 2019-$169.50M-462.8%
FY2018Dec 31, 2018$46.72M–
FY2017Dec 31, 2017-$79.51M–
FY2016Dec 31, 2016-$78.04M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$97.81M–
Q1 FY2026Mar 31, 2026-$133.67M–
Q4 FY2025Dec 31, 2025-$100.06M–
Q3 FY2025Sep 30, 2025-$105.92M–
Q2 FY2025Jun 30, 2025-$79.58M–
Q1 FY2025Mar 31, 2025-$136.55M–
Q4 FY2024Dec 31, 2024-$88.81M–
Q3 FY2024Sep 30, 2024-$63.02M–
Q2 FY2024Jun 30, 2024-$96.01M–
Q1 FY2024Mar 31, 2024-$115.77M–
Q4 FY2023Dec 31, 2023-$100.89M–
Q3 FY2023Sep 30, 2023-$89.43M–
Q2 FY2023Jun 30, 2023-$119.02M–
Q1 FY2023Mar 31, 2023-$61.59M–
Q4 FY2022Dec 31, 2022-$77.51M–
Q3 FY2022Sep 30, 2022-$63.10M–
Q2 FY2022Jun 30, 2022-$45.79M–
Q1 FY2022Mar 31, 2022-$76.15M–
Q4 FY2021Dec 31, 2021-$68.55M-113.4%
Q3 FY2021Sep 30, 2021-$43.31M–
Q2 FY2021Jun 30, 2021-$54.99M–
Q1 FY2021Mar 31, 2021-$53.04M–
Q4 FY2020Dec 31, 2020$512.72M–
Q3 FY2020Sep 30, 2020-$620.00K–
Q2 FY2020Jun 30, 2020-$43.67M–
Q1 FY2020Mar 31, 2020-$55.37M–
Q4 FY2019Dec 31, 2019-$50.42M-155.0%
Q3 FY2019Sep 30, 2019-$33.28M–
Q2 FY2019Jun 30, 2019-$53.45M–
Q1 FY2019Mar 31, 2019-$32.35M-197.9%
Q4 FY2018Dec 31, 2018$91.75M–
Q3 FY2018Sep 30, 2018-$35.67M–
Q2 FY2018Jun 30, 2018-$42.40M–
Q1 FY2018Mar 31, 2018$33.04M–
Q4 FY2017Dec 31, 2017-$19.41M–
Q3 FY2017Sep 30, 2017-$22.29M–
Q2 FY2017Jun 30, 2017-$18.14M–
Q1 FY2017Mar 31, 2017-$19.68M–

More Denali Therapeutics figures

See a number that looks wrong?